KPCM
CPRX

Kings Point Capital Management’s Catalyst Pharmaceutical CPRX Stock Holding History

Kings Point Capital Management’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-6,000
Closed -$15K – 378
2017
Q3 		$15K Buy
+6,000
New +$16.5K ﹤0.01% 322

Other funds holding CPRX

BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return

Kings Point Capital Management's CPRX Position: Q4 2017 in Review

Kings Point Capital Management sold out of Catalyst Pharmaceutical (CPRX) in Q4 2017, closing a stake of 6,000 shares — an estimated $15K sold.

Kings Point Capital Management first reported a position in CPRX in Q3 2017 and held it in 1 quarter. The position peaked at $15K in Q3 2017. 105 funds tracked by Wall St. Rank hold CPRX as of Q4 2017.

  • Kings Point Capital Management reported no remaining Catalyst Pharmaceutical position as of Q4 2017 after selling out during the quarter.
  • Kings Point Capital Management sold 6,000 Catalyst Pharmaceutical shares in Q4 2017, an estimated $15K.
  • Kings Point Capital Management first reported a position in Catalyst Pharmaceutical in Q3 2017 and held it in 1 quarter.
  • Kings Point Capital Management's Catalyst Pharmaceutical position peaked at $15K in Q3 2017.
  • 105 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q4 2017.

Based on Kings Point Capital Management's 13F filing for Q4 2017, filed 13 Feb 2018.